- Home
- WEA vs FBRX Comparison
WEA vs FBRX Comparison
Compare WEA & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- FBRX
- Stock Information
- Founded
- WEA 2002
- FBRX N/A
- Country
- WEA United States
- FBRX United States
- Employees
- WEA N/A
- FBRX N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- WEA Finance
- FBRX Health Care
- Exchange
- WEA Nasdaq
- FBRX Nasdaq
- Market Cap
- WEA 129.9M
- FBRX 154.5M
- IPO Year
- WEA N/A
- FBRX N/A
- Fundamental
- Price
- WEA $11.41
- FBRX $12.34
- Analyst Decision
- WEA
- FBRX Strong Buy
- Analyst Count
- WEA 0
- FBRX 3
- Target Price
- WEA N/A
- FBRX $68.00
- AVG Volume (30 Days)
- WEA 46.1K
- FBRX 76.0K
- Earning Date
- WEA 01-01-0001
- FBRX 11-13-2025
- Dividend Yield
- WEA 7.87%
- FBRX N/A
- EPS Growth
- WEA N/A
- FBRX N/A
- EPS
- WEA N/A
- FBRX N/A
- Revenue
- WEA N/A
- FBRX N/A
- Revenue This Year
- WEA N/A
- FBRX N/A
- Revenue Next Year
- WEA N/A
- FBRX N/A
- P/E Ratio
- WEA N/A
- FBRX N/A
- Revenue Growth
- WEA N/A
- FBRX N/A
- 52 Week Low
- WEA $9.60
- FBRX $4.11
- 52 Week High
- WEA $11.29
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- WEA 81.30
- FBRX 62.78
- Support Level
- WEA $11.17
- FBRX $10.11
- Resistance Level
- WEA $11.18
- FBRX $11.57
- Average True Range (ATR)
- WEA 0.09
- FBRX 0.86
- MACD
- WEA 0.03
- FBRX 0.05
- Stochastic Oscillator
- WEA 94.96
- FBRX 89.51
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).